Monte Rosa Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts)(unaudited) | Shares | Amount | Additionalpaid-incapital | Accumulatedothercomprehensive loss | Accumulateddeficit | TotalStockholders’equity |
| Balance—January 1, 2023 | 49,323,531 | $5 | $503,696 | $(1,752) | $(230,536) | $271,413 |
| Restricted common stock vesting | 33,192 | — | — | — | — | — |
| Exercise of common stock options | 4,261 | — | 18 | — | — | 18 |
| Provision for pension benefit obligation | — | — | — | 14 | — | 14 |
| Stock-based compensation expense | — | — | 3,974 | — | — | 3,974 |
| Unrealized gain on available-for-sale securities | — | — | — | 345 | — | 345 |
| Net Loss | — | — | — | — | (32,038) | (32,038) |
| Balance—March 31, 2023 | 49,360,984 | $5 | $507,688 | $(1,393) | $(262,574) | $243,726 |
| Restricted common stock vesting | 32,185 | — | — | — | — | — |
| Exercise of common stock options | 147,333 | — | 897 | — | — | 897 |
| Provision for pension benefit obligation | — | — | — | 14 | — | 14 |
| Stock-based compensation expense | — | — | 4,153 | — | — | 4,153 |
| Unrealized loss on available-for-sale securities | — | — | — | (261) | — | (261) |
| Issuance of shares under employee stock purchase plan | 51,977 | — | 303 | — | — | 303 |
| Net Loss | — | — | — | — | (35,178) | (35,178) |
| Balance—June 30, 2023 | 49,592,479 | $5 | $513,041 | $(1,640) | $(297,752) | $213,654 |
| Balance—January 1, 2024 | 50,140,233 | $5 | $547,857 | $(2,724) | $(365,888) | $179,250 |
| Restricted common stock vesting | 4,691 | — | — | — | — | — |
| Exercise of common stock options | 45,108 | — | 246 | — | — | 246 |
| Provision for pension benefit obligation | — | — | — | 35 | — | 35 |
| Stock-based compensation expense | — | — | 4,873 | — | — | 4,873 |
| Unrealized loss on available-for-sale securities | — | — | — | (4) | — | (4) |
| Issuance of common stock pursuant to the at-the-market sales agreement | 10,272 | — | 87 | — | — | 87 |
| Net Loss | — | — | — | — | (31,968) | (31,968) |
| Balance—March 31, 2024 | 50,200,304 | $5 | $553,063 | $(2,693) | $(397,856) | $152,519 |
| Restricted common stock vesting | 85,249 | — | — | — | — | — |
| Exercise of common stock options | 190,160 | — | 422 | — | — | 422 |
| Provision for pension benefit obligation | — | — | — | 35 | — | 35 |
| Stock-based compensation expense | — | — | 4,502 | — | — | 4,502 |
| Unrealized loss on available-for-sale securities | — | — | — | (12) | — | (12) |
| Issuance of shares under employee stock purchase plan | 93,859 | — | 298 | — | — | 298 |
| Issuance of common stock pursuant to the at-the-market sales agreement, net of issuance costs of $89 | 120,234 | — | 797 | — | — | 797 |
| Issuance of common stock pursuant to the Underwritten Public Offering, net of issuance cost of $3,290 | 10,638,476 | 1 | 46,709 | — | — | 46,710 |
| Issuance of pre-funded warrant, net of issuance costs of $290 | — | — | 49,710 | — | — | 49,710 |
| Net Loss | — | — | — | — | (30,310) | (30,310) |
| Balance—June 30, 2024 | 61,328,282 | $6 | $655,501 | $(2,670) | $(428,166) | $224,671 |
See accompanying notes to the condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.